share_log

Otonomy (NASDAQ:OTIC) Research Coverage Started at StockNews.com

Otonomy (NASDAQ:OTIC) Research Coverage Started at StockNews.com

Otonomy(納斯達克股票代碼:OTIC)的研究報道始於 StockNews.com
Defense World ·  2023/05/01 01:23

Research analysts at StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report issued to clients and investors on Monday. The firm set a "hold" rating on the biopharmaceutical company's stock.

StockNews.com的研究分析師開始報道以下股票 Otonomy(納斯達克股票代碼:OTIC — 獲取評級) 在週一向客戶和投資者發佈的研究報告中。該公司對這家生物製藥公司的股票設定了 “持有” 評級。

Otonomy Price Performance

Otonomy 價格表現

Shares of Otonomy stock opened at $0.01 on Monday. Otonomy has a 1 year low of $0.01 and a 1 year high of $2.54. The company has a market capitalization of $582,479.50, a P/E ratio of -0.01 and a beta of 1.54. The business has a 50 day moving average price of $0.08 and a 200 day moving average price of $0.10.

週一,Otonomy股票開盤價爲0.01美元。Otonomy的1年低點爲0.01美元,爲1年來的最高水平,爲2.54美元。該公司的市值爲582,479.50美元,市盈率爲-0.01,beta值爲1.54。該企業的50天移動平均價格爲0.08美元,200天移動平均價格爲0.10美元。

Get
獲取
Otonomy
自治學
alerts:
警報:

Institutional Trading of Otonomy

Otonomy的機構交易

Several institutional investors have recently made changes to their positions in OTIC. Two Sigma Investments LP boosted its position in Otonomy by 129.2% in the 3rd quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 80,153 shares during the last quarter. Requisite Capital Management LLC acquired a new stake in Otonomy during the third quarter worth about $44,000. State Street Corp grew its position in Otonomy by 5.1% in the 1st quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock worth $437,000 after purchasing an additional 8,839 shares during the last quarter. Lynx1 Capital Management LP grew its position in Otonomy by 7,609.6% in the 3rd quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after purchasing an additional 2,282,880 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Otonomy in the 3rd quarter worth about $1,621,000. 41.23% of the stock is owned by hedge funds and other institutional investors.

幾位機構投資者最近改變了他們在OTIC的頭寸。Two Sigma Investments LP在第三季度將其在Otonomy的地位提高了129.2%。Two Sigma Investments LP在上個季度又購買了80,153股股票後,現在擁有這家生物製藥公司的142,183股股票,價值42,000美元。Rexcile Capital Management LLC在第三季度收購了Otonomy的新股份,價值約44,000美元。State Street Corp在第一季度將其在Otonomy的地位增長了5.1%。State Street Corp在上個季度又購買了8,839股股票後,現在擁有這家生物製藥公司的182,239股股票,價值43.7萬美元。Lynx1 Capital Management LP在第三季度將其在Otonomy的地位增長了7,609.6%。Lynx1 Capital Management LP在上個季度又購買了2,282,880股股票後,現在擁有這家生物製藥公司的2312,880股股票,價值68.2萬美元。最後,Point72 Asset Management L.P. 在第三季度購買了Otonomy的新頭寸,價值約16.1萬美元。該股的41.23%由對沖基金和其他機構投資者持有。

About Otonomy

關於自主學

(Get Rating)

(獲取評分)

Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.

Otonomy, Inc是一家生物製藥公司。從事神經病學療法的開發。該公司的產品線包括OTIVIDEX(地塞米松)梅尼爾病、OTIPRIO(環丙沙星視力懸浮液)急性帶管中耳炎(AOMT)、OTO-313(加環素)耳鳴、OTO-413(BDNF)隱性聽力損失、OTO-510(耳保護劑)預防CIHL、OTO-6XX(毛細胞再生)嚴重聽力損失。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on Otonomy (OTIC)
  • MarketBeat Week in Review – 4/24 – 4/28
  • How to Invest in the Top Grocery Stocks for This Year
  • Array Technologies Brings Solar Flare To 2023 Earnings Forecast
  • Best Bank Stocks to Invest in Ahead of Rising Interest Rates
  • How to Invest in Farmland: 7 Simple Ways
  • 免費獲取 StockNews.com 關於自主學的研究報告(OTIC)的副本
  • MarketBeat 週迴顧 — 4 月 24 日 — 4 月 28 日
  • 如何投資今年最熱門的雜貨股
  • Array Technologies將太陽耀斑帶入
  • 在利率上升之前投資的最佳銀行股
  • 如何投資農田:7 種簡單方法

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Otonomy Daily 的新聞和評級 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Otonomy及相關公司的最新新聞和分析師評級的簡明每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論